Glaukos

Biotech & Life Sciences · Aliso Viejo, United States · Founded 1998 · IPO 2015

Breakthrough products and procedures to transform the treatment of glaucoma, one of the world’s leading causes of blindness

Valuation $9.65B

Revenue $691M

EBITDA $5.8M

Power Law Unicorn$1–10B valuation tier Thoroughbred$100M+ revenue

Talent graph

Glaukos's talent

Book a demo to see the people

Employees mapped 1,125 incl. 1 AI specialist

Founders /100 quality score

Key operators 23 quality /100

Potential founders likely future founders

Startup mafia 7 alumni-founded startups

Talent movements in · out past 12 months

Source: Dealroom Talent Intelligence.

Investors

15 investors on Glaukos's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 6 investors entered at this stage

Versant Ventures

DeNovo Ventures

Borealis Ventures

Domain Associates

Prism Venture Management

Frazier Healthcare Partners

Series B+ 9 investors entered at this stage

Meritech Capital

University of California

Irvine

Fjord Ventures

InterWest Partners

OrbiMed

Caltech

California Institute of Technology

Montreux Equity Partners

Glaukos mafia

Startups founded by Glaukos alumni

Former Glaukos employees who went on to start their own companies. Sorted by Dealroom signal score.

Stylus MedicineEst. 2022

Joshua ResnickUnited States

Signal score80

VentriJectEst. 2018

Stig Visti AndersenDenmark

Signal score79

Remedium bioEst. 2020

Alex GoraltchoukUnited States

Signal score77

CloraEst. 2016

Rahul ChaturvediUnited States

Signal score76

Nalu MedicalEst. 2014

Mike PartschUnited States

Signal score76

InveniasEst. 2005

Richard HarrisonUnited Kingdom

Signal score65

KSQ TherapeuticsEst. 2015

David BerryUnited States

Signal score63

Book a demo to explore the full alumni network →

Global footprint

Where Glaukos has talent and traffic

Workforce by country

23 countries with
team presence

🇺🇸 United States83.7%

🇩🇪 Germany2.8%

🇬🇧 United Kingdom2%

🇧🇷 Brazil1.7%

🇦🇺 Australia1.4%

Top 5 of 23 shown

Web traffic by country

31K monthly visits
across markets

🇺🇸 United States46.1%

🇬🇧 United Kingdom11.9%

🇦🇺 Australia6.8%

🇮🇳 India6.8%

🇲🇽 Mexico6.1%

Top 5 markets shown

Patent intelligence

$156M patent portfolio · 133 active families

Estimated portfolio value

$156M

1.6% of market cap · 2.3× smaller than top peer NovoCure ($352M)

133 active patent families

Where Glaukos innovates Biomedical engineeringCorneaOphthalmologyOptometryAqueous humor

Where Glaukos concentrates vs peers

Each axis is a top-10 topic across Glaukos and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Glaukos

An AI-synthesized read of the highest-engagement posts about Glaukos on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Glaukos on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles